Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world

BACKGROUND/AIMS: Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of DCV and ASV combination therapy for patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Jae Young, Kim, Byung Seok, Lee, Chang Hyeong, Song, Jeong Eun, Lee, Heon Ju, Park, Jung Gil, Hwang, Jae Seok, Chung, Woo Jin, Jang, Byoung Kuk, Kweon, Young Oh, Tak, Won Young, Park, Soo Young, Jang, Se Young, Suh, Jeong Ill, Kwak, Sang Gyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Association of Internal Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610199/
https://www.ncbi.nlm.nih.gov/pubmed/29792020
http://dx.doi.org/10.3904/kjim.2017.368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6610199/
https://www.ncbi.nlm.nih.gov/pubmed/29792020
http://dx.doi.org/10.3904/kjim.2017.368

Ejemplares similares